BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29:787-793. [PMID: 24224567 DOI: 10.1111/jgh.12452] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
2 Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther 2017;45:1514-23. [DOI: 10.1111/apt.14066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
3 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
4 Yamakado K, Hirota S. Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. World J Gastroenterol 2015;21:10604-8. [PMID: 26457020 DOI: 10.3748/wjg.v21.i37.10604] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
5 Hirooka M, Hiraoka A, Ochi H, Kisaka Y, Joko K, Michitaka K, Hiasa Y. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. AJR Am J Roentgenol 2018;210:891-8. [PMID: 29412017 DOI: 10.2214/AJR.17.18177] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 Kim JH, Shim JH, Lee HC, Sung KB, Ko HK, Ko GY, Gwon DI, Kim JW, Lim YS, Park SH. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017;37:1861-1868. [PMID: 28581250 DOI: 10.1111/liv.13487] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
7 Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA. LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. Am J Gastroenterol. 2016;111:70-77. [PMID: 26729544 DOI: 10.1038/ajg.2015.389] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
8 Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Wang JH, Yen YH. Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center. PLoS One 2020;15:e0230897. [PMID: 32218593 DOI: 10.1371/journal.pone.0230897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Scaffaro LA, Stella SF, Alvares-Da-Silva MR, Kruel CD. Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. World J Hepatol. 2015;7:628-632. [PMID: 25848487 DOI: 10.4254/wjh.v7.i3.628] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
10 Tian Y, Lyu H, He Y, Kanduri HK. Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC. J Gastrointest Cancer 2019;50:400-7. [PMID: 29512001 DOI: 10.1007/s12029-018-0085-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mocan T, Nenu I, Crăciun R, Spârchez Z. Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare? J Gastroenterol Hepatol 2021;36:1518-28. [PMID: 33326142 DOI: 10.1111/jgh.15376] [Reference Citation Analysis]
12 Angelico M. TACE vs DEB-TACE: Who wins? Dig Liver Dis. 2016;48:796-797. [PMID: 27257050 DOI: 10.1016/j.dld.2016.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
13 Hu KS, Tang B, Yuan J, Lu SX, Li M, Chen RX, Zhang L, Ren ZG, Yin X. A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2019;34:1984-91. [PMID: 30932246 DOI: 10.1111/jgh.14673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Longo L, Rodrigues de Freitas LB, Santos D, Grivicich I, Álvares-da-Silva MR. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy. Am J Clin Oncol 2019;42:466-71. [PMID: 30913090 DOI: 10.1097/COC.0000000000000539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Gao Q, Wang XY, Zhou J, Fan J. Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol. 2015;12:10. [PMID: 25421283 DOI: 10.1038/nrclinonc.2014.122-c1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
16 Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21:10327-10335. [PMID: 26420959 DOI: 10.3748/wjg.v21.i36.10327] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 44] [Article Influence: 9.8] [Reference Citation Analysis]
17 Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, Kudo M, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R. Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. Med Oncol 2016;33:114. [PMID: 27601241 DOI: 10.1007/s12032-016-0827-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, Santis AD, Corte CD, Maida M, Attili AF, Sangiovanni A, Cammà C, La Torre G, Gasbarrini A, Grieco A. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology 2018;17:110-8. [DOI: 10.5604/01.3001.0010.7542] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
19 Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M, Guo RP. Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer. 2016;115:1039-1047. [PMID: 27701389 DOI: 10.1038/bjc.2016.301] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
20 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
21 Cho HJ, Kim SS, Kang SY, Yang MJ, Noh CK, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Kim JH, Cho SW, Cheong JY; Korean Liver Cancer Association. A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status. Gut Liver 2019;13:557-68. [PMID: 31023007 DOI: 10.5009/gnl18444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Yasui Y, Tsuchiya K, Kurosaki M, Takeguchi T, Takeguchi Y, Okada M, Wang W, Kubota Y, Goto T, Komiyama Y, Higuchi M, Takaura K, Hayashi T, Takada H, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Himeno Y, Izumi N. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res 2018;48:442-50. [PMID: 29278654 DOI: 10.1111/hepr.13048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
23 Xu Y, Shen Q, Liu P, Xu Z, Wu P, Lu Z, Chen Y, Huang B, Qian G. Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes. Eur Radiol 2017;27:3877-87. [PMID: 28188425 DOI: 10.1007/s00330-017-4740-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
24 Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, Lu SN. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:358-363. [PMID: 25088668 DOI: 10.1111/jgh.12686] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
25 Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49:14-32. [PMID: 30308081 DOI: 10.1111/hepr.13259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
26 Kimura H, Ohkawa K, Miyazaki M, Sakakibara M, Imanaka K, Tamura T, Sueyoshi H, Takada R, Fukutake N, Uehara H, Ashida R, Ioka T, Nakazawa T, Nakanishi K, Katayama K. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. Hepatol Int. 2017;11:105-114. [PMID: 27766479 DOI: 10.1007/s12072-016-9771-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol. 2015;7:406-424. [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 10.8] [Reference Citation Analysis]
28 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 94] [Article Influence: 19.7] [Reference Citation Analysis]
29 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Azemoto R, Shinozaki M, Yoshikawa M, Yokosuka O. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. PLoS One 2015;10:e0125244. [PMID: 25919025 DOI: 10.1371/journal.pone.0125244] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
30 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
32 Dasse KD, Lander MJ, Novelli PM. Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma. J Adv Pract Oncol 2016;7:764-78. [PMID: 29670812 DOI: 10.6004/jadpro.2016.7.7.8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Campigotto M, Giuffrè M, Colombo A, Visintin A, Aversano A, Budel M, Masutti F, Abazia C, Crocé LS. Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature. World J Hepatol 2020;12:1239-57. [PMID: 33442451 DOI: 10.4254/wjh.v12.i12.1239] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
34 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Yamamoto S, Matsuo K, Nishida N, Aramaki T, Anai H, Kora S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). Jpn J Radiol 2014;32:644-9. [DOI: 10.1007/s11604-014-0358-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
35 Wei W, Yang Z, Lu L, Li J, Lei Z, Wang K, Xia Y, Yan Z, Shen F. Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. International Journal of Surgery 2018;56:256-63. [DOI: 10.1016/j.ijsu.2018.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]